| Market Capitalization (Millions $) |
2,483 |
| Shares
Outstanding (Millions) |
85 |
| Employees |
76 |
| Revenues (TTM) (Millions $) |
- |
| Net Income (TTM) (Millions $) |
-350 |
| Cash Flow (TTM) (Millions $) |
11 |
| Capital Exp. (TTM) (Millions $) |
0 |
Business Description
Mineralys Therapeutics Inc is a biotechnology company that focuses on developing novel therapeutics for the treatment of mineralization disorders. These disorders involve the abnormal accumulation or depletion of minerals, such as calcium, phosphate, or magnesium, in the body.
The company's primary goal is to improve the understanding of mineralization disorders and develop innovative therapies that can restore normal mineral balance. They utilize cutting-edge research and scientific methods to identify potential therapeutic targets and develop drugs that can effectively modulate mineralization processes.
Mineralys Therapeutics Inc works closely with academic institutions, research organizations, and pharmaceutical companies to advance their drug discovery and development programs. They conduct preclinical and clinical trials to evaluate the safety and efficacy of their drug candidates, with the ultimate aim of bringing new treatments to patients in need.
Overall, Mineralys Therapeutics Inc is dedicated to addressing the unmet medical needs of individuals suffering from mineralization disorders and improving their quality of life through the development of innovative therapeutics.
Company Address: 150 N. Radnor Chester Road Radnor 19087 PA
Company Phone Number: 378-6240 Stock Exchange / Ticker: NASDAQ MLYS
|
